EXEL Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of 27.14%. Exelixis, Inc.'s return on equity of 31.26% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Exelixis, Inc. has a consensus price target of $44.94, signalling upside risk potential of 1.3%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 35.51%. Given that ADMA Biologics, Inc. has higher upside potential than Exelixis, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $597.8M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. Exelixis, Inc.'s net income of $193.6M is higher than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 18.68x while ADMA Biologics, Inc.'s PE ratio is 23.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.55x versus 10.12x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Aldeyra Therapeutics, Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of --. Exelixis, Inc.'s return on equity of 31.26% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

Exelixis, Inc. has a consensus price target of $44.94, signalling upside risk potential of 1.3%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 98.09%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Exelixis, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $597.8M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Exelixis, Inc.'s net income of $193.6M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 18.68x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.55x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of 33.68%. Exelixis, Inc.'s return on equity of 31.26% beat Merck & Co., Inc.'s return on equity of 39.63%.

Exelixis, Inc. has a consensus price target of $44.94, signalling upside risk potential of 1.3%. On the other hand Merck & Co., Inc. has an analysts' consensus of $105.92 which suggests that it could grow by 4.99%. Given that Merck & Co., Inc. has higher upside potential than Exelixis, Inc., analysts believe Merck & Co., Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.21% to investors and pays a quarterly dividend of $0.81 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Exelixis, Inc. quarterly revenues are $597.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Exelixis, Inc.'s net income of $193.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Exelixis, Inc.'s price-to-earnings ratio is 18.68x while Merck & Co., Inc.'s PE ratio is 13.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.55x versus 3.98x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 32.38% compared to Exelixis, Inc.'s net margin of -40.15%. Exelixis, Inc.'s return on equity of 31.26% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Exelixis, Inc. has a consensus price target of $44.94, signalling upside risk potential of 1.3%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 125.96%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Exelixis, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Exelixis, Inc..

Exelixis, Inc. has a beta of 0.400, which suggesting that the stock is 59.967% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Exelixis, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Exelixis, Inc. quarterly revenues are $597.8M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Exelixis, Inc.'s net income of $193.6M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Exelixis, Inc.'s price-to-earnings ratio is 18.68x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis, Inc. is 5.55x versus 1.44x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.